首页> 外文期刊>Human Pathology >Triple marker composed of p16, CD56, and TTF1 shows higher sensitivity than INSM1 for diagnosis of pulmonary small cell carcinoma: proposal for a rational immunohistochemical algorithm for diagnosis of small cell carcinoma in small biopsy and cytology specimens
【24h】

Triple marker composed of p16, CD56, and TTF1 shows higher sensitivity than INSM1 for diagnosis of pulmonary small cell carcinoma: proposal for a rational immunohistochemical algorithm for diagnosis of small cell carcinoma in small biopsy and cytology specimens

机译:由P16,CD56和TTF1组成的三重标记显示比INSM1更高的敏感性,用于诊断肺部小细胞癌的诊断:用于诊断小型活组织检查和细胞学标本中小细胞癌的合理免疫组织化学算法的提议

获取原文
获取原文并翻译 | 示例
           

摘要

Pulmonary small cell carcinoma (SCLC) can be usually diagnosed based on the morphological evaluation of routine histological or cytological preparations. However, immunohistochemistry may be also necessary in problematic cases. Insulinoma-associated 1 (INSM1) has recently been reported as a highly sensitive and specific marker that displays positivity in similar to 90%-400% of poorly differentiated pulmonary neuroendocrine tumors. We compared diagnostic performance of INSM1 and previously reported composite marker CD56 + p16 + thyroid transcription factor-1 (TTF1) in the diagnosis of SCLC in small biopsy specimens and cytoblocks. The composite marker CD56 + p16 + TTF1 correctly classified 100% of SCLC cases, and its sensitivity was significantly higher than the sensitivity of INSM1. Among 100 SCLC cases, CD56, TTF1, and p16 each individually classified more specimens correctly than INSM1 (CD56: 84%, TTF1: 89%, p16: 95%, INSM1: 81%); the difference was statistically significant only for p16. INSM1 showed the lowest classification agreement between paired biopsy and cytoblock specimens (k = 0.182), whereas CD56 and p16 displayed perfect agreement (k = 1) and TTF1 showed moderate agreement (k= 0.4). Although INSM1 is reportedly the most specific marker of SCLC, its sensitivity is not superior to p16 or composite marker CD56 + TTF1 + p16. Based on this study, we propose the following algorithm, which, in the appropriate clinical and histological context, may be useful in establishing the correct diagnosis of SCLC: First, INSM1 detection is performed, and if the result is negative, CD56 is added, followed successively by p16 and TTF1 if all previously applied markers are negative. This approach should detect most, if not all, SCLC cases, while successively trading specificity for sensitivity. (C) 2018 Elsevier Inc. All rights reserved.
机译:肺部小细胞癌(SCLC)通常可以根据常规组织学或细胞学制剂的形态学评估诊断。然而,在有问题的情况下也可能需要免疫组织化学。最近据报道了胰岛素相关的1(INSM1)作为高度敏感和特异性标志物,其显示出与90%-400%的阳性较差的肺部神经内分泌肿瘤相似。我们将INSM1和先前报道的复合标记CD56 + P16 +甲状腺转录因子-1(TTF1)的诊断性能进行了比较了SCLC中的小型活组织检查标本和细胞组织。复合标志物CD56 + P16 + TTF1正确分类了100%的SCLC病例,其敏感性显着高于INSM1的灵敏度。在100个SCLC病例中,CD56,TTF1和P16各自单独分类更多的样品,比INSM1正确(CD56:84%,TTF1:89%,P16:95%,INSM1:81%);对于p16,差异是统计学意义的。 insm1显示了成对的活检和细胞组织标本(k = 0.182)之间的最低分类协议,而CD56和P16显示完美的协议(k = 1)和TTF1显示中等协议(k = 0.4)。据报道,虽然INSM1是SCLC最具体的标记,但其敏感性不优于P16或复合标记CD56 + TTF1 + P16。基于这项研究,我们提出了以下算法,在适当的临床和组织学背景下,可以有用在建立SCLC的正确诊断:首先,进行INSM1检测,如果结果为负,则添加CD56,如果所有先前应用的标记为负,则由P16和TTF1连续接着。这种方法应该检测到大多数,如果不是全部,SCLC病例,同时连续交易敏感性的特异性。 (c)2018年Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号